1. Scrip
  2. >>Therapy Areas

Gilead Data Suggest Role For ACC Inhibition In NASH

 
• By Joseph Haas

With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.

scientists doing lab research on digital screen

Gilead Sciences Inc. presented data at the American Association for the Study of Liver Diseases annual meeting indicating a potential role for acetyl-coA-carboxylase (ACC) inhibition in the treatment of non-alcoholic steatohepatitis (NASH), as the higher of two doses tested in a Phase II study showed a statistically significant reduction in the buildup of fat in the liver compared to placebo after 12 weeks of treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.